The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.
Clinical
Ovarian malignant mesoderm mixed tumor
Pathology
Prognosis
Treatment
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
16 Sep 2022
16 Sep 2022
Historique:
received:
20
06
2022
accepted:
30
08
2022
entrez:
16
9
2022
pubmed:
17
9
2022
medline:
21
9
2022
Statut:
epublish
Résumé
Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. To provide reference for the treatment and prognosis of OMMMT, we analyzed the clinical features, pathology and molecular biology characteristic of published cases. The English and Chinese reported cases of OMMMT were selected from PubMed, Clinical Trials.gov and CNKI database from 2000 to December 15th, 2021 following the PRISMA guidelines. A total of 63 literatures including 199 OMMMT cases were included. The average age of patients at diagnosis was 56.46 years, the highest incidence age was 60-65 years, and 82% of them were menopausal women. Most patients were diagnosed in FIGO III stage (59.64%). The most common symptom of OMMMT was abdominal pain (60.5%). 61.6% of patients were accompanied by ascites, while ascites was not associated with metastatic tumor and local recurrence. The CA125 of 88.68% patients increased. The most common reported carcinomatous component and sarcomatous component were serous adenocarcinoma (44.96%) and chondrosarcoma (24.81%), respectively. Initial treatment included surgery (94.97%) and taxanes-based (55.10%) or platinum-based (85.71%) chemotherapy regimens. The median survival time of patients was 20 months. Heterologous sarcoma component did not shorten life expectancy. The optimal ovarian tumor cell debulking surgery (OOTCDS), radiotherapy and chemotherapy could significantly prolong the median survival time of patients. Furthermore, platinum drugs could significantly prolong the survival time after comparing various chemotherapy schemes. Besides, the combination of platinum and taxanes was therapeutically superior to the combination of platinum and biological alkylating agents. The OOTCDS and platinum-based chemotherapy regimen can improve the prognosis of OMMMT. Targeted therapy might become a new research direction in the future. Since the elderly patients are the majority, the toxicity of new drugs on the elderly patients is more noteworthy.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. To provide reference for the treatment and prognosis of OMMMT, we analyzed the clinical features, pathology and molecular biology characteristic of published cases.
METHODS
METHODS
The English and Chinese reported cases of OMMMT were selected from PubMed, Clinical Trials.gov and CNKI database from 2000 to December 15th, 2021 following the PRISMA guidelines.
RESULTS
RESULTS
A total of 63 literatures including 199 OMMMT cases were included. The average age of patients at diagnosis was 56.46 years, the highest incidence age was 60-65 years, and 82% of them were menopausal women. Most patients were diagnosed in FIGO III stage (59.64%). The most common symptom of OMMMT was abdominal pain (60.5%). 61.6% of patients were accompanied by ascites, while ascites was not associated with metastatic tumor and local recurrence. The CA125 of 88.68% patients increased. The most common reported carcinomatous component and sarcomatous component were serous adenocarcinoma (44.96%) and chondrosarcoma (24.81%), respectively. Initial treatment included surgery (94.97%) and taxanes-based (55.10%) or platinum-based (85.71%) chemotherapy regimens. The median survival time of patients was 20 months. Heterologous sarcoma component did not shorten life expectancy. The optimal ovarian tumor cell debulking surgery (OOTCDS), radiotherapy and chemotherapy could significantly prolong the median survival time of patients. Furthermore, platinum drugs could significantly prolong the survival time after comparing various chemotherapy schemes. Besides, the combination of platinum and taxanes was therapeutically superior to the combination of platinum and biological alkylating agents.
CONCLUSION
CONCLUSIONS
The OOTCDS and platinum-based chemotherapy regimen can improve the prognosis of OMMMT. Targeted therapy might become a new research direction in the future. Since the elderly patients are the majority, the toxicity of new drugs on the elderly patients is more noteworthy.
Identifiants
pubmed: 36114551
doi: 10.1186/s13048-022-01037-6
pii: 10.1186/s13048-022-01037-6
pmc: PMC9482291
doi:
Substances chimiques
Alkylating Agents
0
Taxoids
0
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Subventions
Organisme : National Nature Science Foundation of China
ID : 81903948, 81873330
Organisme : National Nature Science Foundation of China
ID : 81903948, 81873330
Informations de copyright
© 2022. The Author(s).
Références
J Clin Pathol. 2006 May;59(5):460-7
pubmed: 16461565
Cancer Causes Control. 2006 Jun;17(5):655-62
pubmed: 16633912
J Clin Oncol. 2006 Dec 20;24(36):5658-63
pubmed: 17102066
Proteomes. 2022 May 09;10(2):
pubmed: 35645374
J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226
pubmed: 33545690
Am J Clin Oncol. 2015 Jun;38(3):272-7
pubmed: 23751320
Oncol Rep. 2017 Sep;38(3):1464-1472
pubmed: 28713970
J Ovarian Res. 2019 Apr 4;12(1):32
pubmed: 30947745
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
pubmed: 21685461
J Clin Oncol. 2002 Jun 1;20(11):2758-60
pubmed: 12039943
Obstet Gynecol Sci. 2020 Nov;63(6):709-718
pubmed: 32937685
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
BMC Cancer. 2018 Feb 9;18(1):172
pubmed: 29426293
Histopathology. 2000 Nov;37(5):427-36
pubmed: 11119124
Cancer Res. 2013 Dec 1;73(23):6900-12
pubmed: 23975756
Int J Environ Res Public Health. 2022 Jan 19;19(3):
pubmed: 35162125
Crit Rev Oncol Hematol. 2019 Feb;134:46-55
pubmed: 30771873
J Ovarian Res. 2018 Oct 1;11(1):88
pubmed: 30270814
Cancer. 1998 May 1;82(9):1731-7
pubmed: 9576296
Gynecol Oncol. 2005 Jan;96(1):136-42
pubmed: 15589592
Eur J Obstet Gynecol Reprod Biol. 2021 Jul;262:134-141
pubmed: 34022590
Gynecol Oncol. 2014 May;133(2):234-7
pubmed: 24631447
Cancer. 2004 May 15;100(10):2148-53
pubmed: 15139057
Histopathology. 1998 Jan;32(1):69-80
pubmed: 9522220
Int J Hematol Oncol Stem Cell Res. 2015 Jan 1;9(1):1-4
pubmed: 25802693
Hum Reprod Update. 2022 May 2;28(3):417-434
pubmed: 35199161
Gynecol Oncol. 2013 Oct;131(1):46-51
pubmed: 23906658
PLoS One. 2017 Jan 26;12(1):e0170879
pubmed: 28125702
Gynecol Oncol. 2004 Dec;95(3):583-7
pubmed: 15581967
Int J Cancer. 2017 Apr 15;140(8):1860-1869
pubmed: 28032649
Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1025-30
pubmed: 17466043
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):809-12
pubmed: 17892455
Hippokratia. 2015 Jul-Sep;19(3):256-9
pubmed: 27418786
Hum Reprod. 2006 May;21(5):1237-42
pubmed: 16431901
Int J Gynecol Pathol. 2019 Jul;38(4):386-392
pubmed: 29620581
J Ovarian Res. 2020 Oct 28;13(1):129
pubmed: 33115531
Gynecol Oncol. 2011 Jun 1;121(3):477-81
pubmed: 21420726
Acta Cytol. 1986 Mar-Apr;30(2):173-6
pubmed: 3457508
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):316-24
pubmed: 17362309
Gynecol Oncol. 2006 Jan;100(1):128-32
pubmed: 16213011
Front Oncol. 2021 Mar 05;11:645156
pubmed: 33763376
Int J Mol Sci. 2017 May 20;18(5):
pubmed: 28531111
Obstet Gynecol Sci. 2017 Jul;60(4):350-356
pubmed: 28791266
Cureus. 2015 Nov 24;7(11):e389
pubmed: 26719832
J Exp Clin Cancer Res. 2015 Oct 17;34:123
pubmed: 26474755
Ultrasound Obstet Gynecol. 2022 Feb;59(2):241-247
pubmed: 34225386
Gynecol Oncol. 2016 Aug;142(2):248-54
pubmed: 27321238
Clin Exp Metastasis. 2015 Jan;32(1):29-38
pubmed: 25398397
Diagnostics (Basel). 2019 Nov 22;9(4):
pubmed: 31766630
Indian J Pathol Microbiol. 2013 Oct-Dec;56(4):365-71
pubmed: 24441223
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
Autophagy. 2015;11(2):225-38
pubmed: 25607466
Clin Cancer Res. 2017 Oct 1;23(19):5836-5845
pubmed: 28679774
Gynecol Oncol. 2005 Jan;96(1):159-67
pubmed: 15589595
Int J Gynecol Pathol. 2001 Apr;20(2):133-9
pubmed: 11293158
J Control Release. 2010 Sep 15;146(3):264-75
pubmed: 20385184
Gynecol Oncol. 2013 Oct;131(1):42-5
pubmed: 23838036
Int J Gynecol Cancer. 2009 Dec;19(9):1521-3
pubmed: 19955929
Gynecol Oncol. 2010 Apr;117(1):37-40
pubmed: 20117828
APMIS. 2008 Feb;116(2):107-17
pubmed: 18321361
Oncology. 2011;80(1-2):102-6
pubmed: 21677454
Virchows Arch. 2008 Mar;452(3):259-68
pubmed: 18193277
Cell. 2018 Sep 20;175(1):159-170.e16
pubmed: 30241606
Obstet Gynecol Surv. 2009 Oct;64(10):673-80; quiz 697
pubmed: 19772676
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60
pubmed: 25341582
Oncol Lett. 2016 Jul;12(1):459-466
pubmed: 27347165
Clin Nucl Med. 2011 Jun;36(6):460-1
pubmed: 21552025
Int J Gynecol Pathol. 2017 Jan;36(1):64-70
pubmed: 27167672
Int J Surg Pathol. 2015 Sep;23(6):465-71
pubmed: 25911569
J Clin Oncol. 1999 Sep;17(9):2639-48
pubmed: 10561337
Clin Breast Cancer. 2008 Oct;8(5):392-401
pubmed: 18952552
Int J Gynecol Pathol. 2012 May;31(3):211-21
pubmed: 22498937
Arch Gynecol Obstet. 2021 Oct;304(4):1043-1053
pubmed: 33751209
Pathol Oncol Res. 2020 Oct;26(4):2067-2073
pubmed: 32472441
Anticancer Res. 2014 Dec;34(12):7351-6
pubmed: 25503171